Biomarker ID | 361 |
PMID | 18593988 |
Year | 2008 |
Biomarker | Osteopontin |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Recurrent Group (Recurrent Group: 203.2 ± 78.4; Non Recurrent Group: 127.76 ± 76.6) |
Odds Ratio/Hazard Ratio/Relative Risk | OR: 1.01 (95% CI: 1.00-1.01) |
Effect on Pathways | Pathways Include:-Alpha-V beta-3 integrin/OPN pathway,TWEAK regulation of gene expression,Osteopontin signaling,Osteoclast signaling,Beta-3 integrin cell surface interactions |
Experiment | Reccurance Free Survival Vs Recurrance in 5 years |
Type of Biomarker | Prognostic |
Cohort | 103 prostatectomy specimens were obtained with a 72 month follow up period. 53 cases of Biochemical reccurrances and 50 patients with no recurrance. |
Senstivity | 75.5 (Monte Carlo Cross Validation: 75.9 ± 4.2) |
Specificity | 76 (Monte Carlo Cross Validation: 75.6 ± 3.9) |
AUC | 0.767 |
Accuracy | 75.7 ((Monte Carlo Cross Validation: 75.9 ± 2.8) |
Level Of Significance | p<0.001 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | SPP1 |